Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Phase II Dose Finding Study of Revlimid™ and Melphalan in Patients With Previously Untreated Multiple Myeloma

NCT00305812 is registered in ClinicalTrials.gov with NCIC Clinical Trials Group as lead sponsor.

NCT NCT00305812
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00305812 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Phase II Dose Finding Study of Revlimid™ and Melphalan in Patients With Previously Untreated Multiple Myeloma
Lead sponsor
NCIC Clinical Trials Group
Phase
Phase 2
Overall status
Completed
Start date
March 9, 2006
Completion date
June 30, 2008
Enrollment
51 (actual)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma and plasma cell neoplasm